Adult Dosing
Palliative therapy of breast and ovarian adenocarcinoma
- 0.3 to 0.4 mg/kg IV q1-4 wk
Intracavitary effusions (malignant)
- 0.6-0.8 mg/kg intracavitary q1-4 wks
Superficial papillary carcinoma of the urinary bladder
- Intravesical; 60 mg retained for 2 hrs qwk for 4 wks; reposition patient q15 mins for maximum contact. Course may be repeated 2-3 times cautiously (bone marrow depression may occur)
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
- Monitor WBC and platelet counts qwk during therapy and for 3 wk or more after therapy discontinuation
- Thiotepa is highly toxic to the hematopoietic system. Death from septicemia, hemorrhage, bone marrow depression has occurred
- Discontinue treatment or reduce dosage if white blood cell or platelet count decrease rapidly
- This drug can cause fetal harm when administered to a pregnant woman; effective contraception should be used during the therapy if either the patient or the partner is of childbearing potential
- Prior to intravesical instillation, patients should not drink for 8-12 hrs. Patient may be repositioned every 15 min to maximize area of contact during intravesical administration
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Patients with childbearing potential
- Intravesical administration
- Recent X-ray therapy
- Decreased bone marrow reserve
- Active infections
- Other chronic debilitating illnesses
Pregnancy Category:D
Breastfeeding: Safety undetermined. Due to the potential for tumorigenicity shown for thiotepa in animal studies; manufacturer recommends discontinuation of breastfeeding, or discontinuation of treatment (taking into account the importance of the drug to the mother)
